Assessment of Platelets, Total White Blood Cell Counts and Reticulocytes Count in Sickle Cell Disease

https://doi.org/10.65770/IAXI9244

ABSTRACT

Sickle cell disease (SCD) is characterized by chronic hemolysis, persistent inflammatory activation, and recurrent vaso-occlusive events. These pathophysiological processes are reflected in routinely available hematological indices, yet their integrated behavior across clinical states remains incompletely defined. This hospital-based cross-sectional study evaluated platelet count, total white blood cell (WBC) count, and reticulocyte percentage in individuals with confirmed SCD and apparently healthy controls. Patients were further categorized as being in steady state or vaso-occlusive crisis. Comparative analyses were conducted using appropriate parametric or non-parametric tests, with effect sizes and 95% confidence intervals reported. Steady-state SCD patients demonstrated significantly higher platelet counts, WBC counts, and reticulocyte percentages compared with controls (all p < 0.001), with large to very large effect sizes. These parameters were further amplified during crisis, revealing a consistent stepwise gradient from health to steady-state disease and acute exacerbation (overall p < 0.001). Platelet count showed a significant positive correlation with reticulocyte percentage, whereas its association with total WBC count was not statistically significant. The observed hematological gradient supports the conceptualization of SCD as a dynamic thromboinflammatory continuum rather than a static hematologic disorder. Marked reticulocytosis during crisis reflects intensified hemolytic stress, while concurrent leukocytosis and thrombocytosis indicate amplified inflammatory and adhesive activation. Although the crisis subgroup was limited in size, the internal consistency of findings across analytical approaches supports their biological plausibility. These results highlight the potential utility of routine hematological parameters as accessible indicators of disease activity, particularly in resource-constrained settings. Larger longitudinal studies incorporating treatment stratification and expanded biomarker profiling are needed to refine prognostic applications in sickle cell disease.

References

• [1] Ataga, K. I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., … and Rother, R. P. (2017). Crizanlizumab for the prevention of pain crises in sickle cell disease. New England Journal of Medicine, 376(5), 429-439
• [2] Bain, B. J., and Leach, M. (2025). Blood cells: a practical guide. John Wiley and Sons.
• [3] Ballas, S. K., Lieff, S., Benjamin, L. J., Dampier, C. D., Heeney, M. M., Hoppe, C., … and Telen, M. J. (2010). Definitions of the phenotypic manifestations of sickle cell disease. American journal of hematology, 85(1), 6-13.
• [4] Banach, M. (2023). GBD 2021 Sickle Cell Disease Collaborators. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematology, 10(8).
• [5] Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., … and Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (1995). Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine, 332(20), 1317-1322.
• [6] Charan, J., and Biswas, T. (2013). How to calculate sample size for different study designs in medical research? Indian journal of psychological medicine, 35(2), 121-126.
• [7] Cheesbrough, M (2010). District laboratory practice in tropical countries, part 2. Cambridge university press.
• [8] Colella, M. P., de Paula, E. V., Ozelo, M. C., and Traina, F. (2016). Hypercoagulability and Sickle Cell Disease. In Sickle Cell Anemia: From Basic Science to Clinical Practice(pp. 109-127). Cham: Springer International Publishing.
• [9] Conran, N., and De Paula, E. V. (2020). Thromboinflammatory mechanisms in sickle cell disease–challenging the hemostatic balance. Haematologica, 105(10), 2380.
• Curtis, S. A., Danda, N., Etzion, Z., Cohen, H. W., and Billett, H. H. (2015). Elevated steady state WBC and platelet counts are associated with frequent emergency room use in adults with sickle cell anemia. PLoS One, 10(8), e0133116.
• Dacie, J. V., and Lewis, S. M. (2017). Practical hematology (12th ed. s). Elsevier.
• Day, T. G., Drasar, E. R., Fulford, T., Sharpe, C. C., and Thein, S. L. (2012). Association between hemolysis and albuminuria in adults with sickle cell anemia. Haematologica, 97(2), 201.
• de Ligt, L. A., Gaartman, A. E., Biemond, B. J., Fijnvandraat, K., van Bruggen, R., and Nur, E. (2024). Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target. American Journal of Hematology, 99(6), 1119-1128.
• Elmariah, H., Garrett, M. E., De Castro, L. M., Jonassaint, J. C., Ataga, K. I., Eckman, J. R., … and Telen, M. J. (2014). Factors associated with survival in a contemporary adult sickle cell disease cohort. American journal of hematology, 89(5), 530-535.
• Feugray, G., Kasonga, F., Grall, M., Benhamou, Y., Bobée-Schneider, V., Buchonnet, G., … and Billoir, P. (2022). Assessment of reticulocyte and erythrocyte parameters from automated blood counts in vaso-occlusive crisis on sickle cell disease. Frontiers in Medicine, 9, 858911.
• Frantzeskaki, F., Armaganidis, A., and Orfanos, S. E. (2017). Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation. Respiration, 93(3), 212-225.
• Hebbel, R. P. (2011). Reconstructing sickle cell disease: a data‐based analysis of the “hyperhemolysis paradigm” for pulmonary hypertension from the perspective of evidence‐based medicine. American journal of hematology, 86(2), 123-154.
• Karki, N. R., and Kutlar, A. (2021). P-selectin blockade in the treatment of painful vaso-occlusive crises in sickle cell disease: a spotlight on crizanlizumab. Journal of Pain Research, 849-856.
• Klouda, T., Raybagkar, D., Bernstein, B., and Apollonsky, N. (2020). Changes in Blood Profile from Steady State in Patients with Sickle Cell Anemia Admitted for Vaso‐occlusive Crisis and Acute Chest Syndrome. Advances in hematology, 2020(1), 3656717.
• Lwanga, S. K., and Lemeshow, S. (1991). Sample size determination in health studies. Geneva: World Health Organization, 1.
• Moreira, J. A., Laurentino, M. R., Machado, R. P. G., Barbosa, M. C., Gonçalves, R. P., Mota, A. D. M., … and Gonçalves, R. P. (2015). Pattern of hemolysis parameters and association with fetal hemoglobin in sickle cell anemia patients in steady state. Revista Brasileira de Hematologia e Hemoterapia, 37, 167-171.
• Nigeria Population Commission. (2019). Nigeria demographic and health survey 2018. NPC, ICF.
• Noronha, J. F. A., Costa, F. F., Saad, S. T. O., Lorand-Metze, I. G. H., and Grotto, H. Z. W. (2007). Evaluation of reticulated platelets in patients with sickle cell diseases. Thrombosis research, 121(2), 259-267.
• Piel, F. B., Hay, S. I., Gupta, S., Weatherall, D. J., and Williams, T. N. (2013). Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS medicine, 10(7), e1001484.
• Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., and Klug, P. P. (1994). Mortality in sickle cell disease–life expectancy and risk factors for early death. New England Journal of Medicine, 330(23), 1639-1644.
• Proenca-Ferreira, R., Brugnerotto, A. F., Garrido, V. T., Dominical, V. M., Vital, D. M., Ribeiro, M. D. F. R., … and Conran, N. (2014). Endothelial activation by platelets from sickle cell anemia patients. PloS one, 9(2), e89012.
• Quinn, C. T., Lee, N. J., Shull, E. P., Ahmad, N., Rogers, Z. R., and Buchanan, G. R. (2008). Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood, The Journal of the American Society of Hematology, 111(2), 544-548.
• Rees, D. C., Williams, T. N., and Gladwin, M. T. (2010). Sickle-cell disease. Lancet, 376(9757):2018-31
• Serjeant, G. R., Ghosh, K., and Patel, J. (2016). Sickle cell disease in India: a perspective. Indian Journal of Medical Research, 143(1), 21-24.
• Shome, D. K., Jaradat, A., Mahozi, A. I., Sinan, A. S., Ebrahim, A., Alrahim, M., … and Pasha, S. A. A. (2018). The platelet count and its implications in sickle cell disease patients admitted for intensive care. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine, 22(8), 585.
• Sundd, P., Gladwin, M. T., and Novelli, E. M. (2019). Pathophysiology of sickle cell disease. Annual review of pathology: mechanisms of disease, 14(1), 263-292.
• Taylor, J. G., Nolan, V. G., Mendelsohn, L., Kato, G. J., Gladwin, M. T., and Steinberg, M. H. (2008). Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PloS one, 3(5), e2095.
• Turhan, A., Weiss, L. A., Mohandas, N., Coller, B. S., and Frenette, P. S. (2002). Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proceedings of the National Academy of Sciences, 99(5), 3047-3051.
• Villagra, J., Shiva, S., Hunter, L. A., Machado, R. F., Gladwin, M. T., and Kato, G. J. (2007). Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood, The Journal of the American Society of Hematology, 110(6), 2166-2172.
• Ware, R. E. (2010). How I use hydroxyurea to treat young patients with sickle cell anemia. Blood, The Journal of the American Society of Hematology, 115(26), 5300-5311.
• Wun, T., Paglieroni, T., Field, C. L., Welborn, J., Cheung, A., Walker, N. J., and Tablin, F. (1999). Platelet-erythrocyte adhesion in sickle cell disease. Journal of investigative medicine: the official publication of the American Federation for Clinical Research, 47(3), 121-127.

Download all article in PDF

WSN 213 (2026) 49-67

ADVERTISEMENT